Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.38 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24095387 | 0.85 | TGFBR1 (0.38) | IRAK4TGFBR1GRM5KDM5AKDM5B | |
| SCHEMBL24095415 | 0.81 | TGFBR1 (0.43) | IRAK4TGFBR1GRM5PPARG | |
| SCHEMBL24095451 | 0.77 | KDM5A (0.39) | TGFBR1KDM5AKDM5BKDM4CPPARG | |
| SCHEMBL24095386 | 0.74 | TGFBR1 (0.49) | TGFBR1GRM5 | |
| SCHEMBL24095517 | 0.74 | TGFBR1 (0.43) | IRAK4TGFBR1GRM5 | |
| SCHEMBL24095431 | 0.74 | TGFBR1 (0.46) | IRAK4TGFBR1GRM5 | |
| SCHEMBL24095388 | 0.73 | ROCK1 (0.46) | — | |
| SCHEMBL24095461 | 0.68 | ALDH1A1 (0.47) | TGFBR1 | |
| SCHEMBL22186849 | 0.68 | TGFBR1 (0.47) | TGFBR1GRM5 | |
| SCHEMBL191463 | 0.67 | SMN1; SMN2 (0.50) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | JIANGSU AOSAIKANG PHARMACEUTICAL CO., LTD. (CN) | 2022-03-31 | — | — | US | disclosed |
| EP-3922631-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-BETA R1 KINASE INHIBITOR | Jiangsu AoSaiKang Pharmaceutical Co., Ltd. (CN) | 2021-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098171-A1 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR | TGFBR1, TGFBR2, TGFB1 | IRAK4 259/4885TGFBR1 1/4885ACVR1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.